In 2004 Bevacizumab was the first approved drug targeted against all isoforms of VEGF-A; since that, similar several medicines have been developed and successfully used for the treatment of many types of cancer (colorectal cancer, non-squamous cell lung cancer, metastatic renal cell carcinoma and others) reviewed in [64,65]. This evidence concerns the gene VEGFA and cancer.